Eli Lilly and Company has announced a $3-billion expansion of its sterile manufacturing facility in Pleasant Prairie, Wisconsin. Lilly had acquired the facility earlier this year (2024) from Nexus Pharmaceuticals, a Lincolnshire, Illinois-based specialty- and generic-drug manufacturer of injectable drugs.   

The expansion will extend Lilly’s global parenteral (injectable) product manufacturing network to support its diabetes and obesity drugs and future pipeline medicines across other therapeutic areas. Lilly expects to add 750 jobs to the current 100-plus workforce at this location. 

The acquisition, expansion, and additional purchases of land and the adjacent warehouse bring Lilly’s total planned investment in Wisconsin to $4 billion. The expanded facility will focus on manufacturing injectable medicines, device assembly, and packaging for medicines across multiple therapeutic areas. 

The company plans to start construction of the expansion next year (2025). Since 2020, Lilly has committed more than $23 billion to construct, expand and acquire manufacturing sites worldwide. 

Source: Eli Lilly and Company